Prophylactic and therapeutic efficacy of berberine on chronic toxoplasmosis in diabetic or hypertensive mice

Abd El Wahab, Wegdan; Ismail, Mousa; Zalat, R Abab; Gh Ieth, Marwa; Abdel Gawa D, Samah; Ahme D, Marwa; M Ousa, Amr; Faro Uk, Raghda; Mona I Ali, Mona

doi:10.21608/puj.2024.304987.1257

|
|
|
How to cite
RIS EndNote BibTeX APA MLA Harvard Vancouver
|
Share

	Prophylactic and therapeutic efficacy of berberine on chronic toxoplasmosis in diabetic or hypertensive mice
Article 8, Volume 17, Issue 2, August 2024, Page 126-134 PDF (1.48 MB)
Document Type: Original Article
DOI: 10.21608/puj.2024.304987.1257
View on SCiNiTO
Authors
Wegdan Abd El Wahab ¹; Mousa Ismail²; R abab Zalat³; Marwa Gh ieth⁴; Samah Abdel Gawa d⁵; Marwa Ahme d⁶; Amr M ousa⁷; Raghda Faro uk⁸; Mona Mona I Ali⁸
¹Departments of Medical Parasitology , Faculties of Medicine, Beni- Suef and Theodor Bilharz Research Institute , Beni-Suef , Egypt
²Faculties of Medicine,, Beni- Suef , Cairo ,Egypt
³Departments of Medical Parasitology, Theodor Bilharz Research Institute , Giza , Egypt
⁴Departments of Medical Parasitology, Faculties of Medicine,Beni- Suef ,Beni-Suef
⁵Departments of Medical Parasitology, Faculties of Medicine,Beni- Suef ,Beni-Suef, Egypt
⁶Departments of Pathology, Faculties of Medicine,Beni- Suef , Beni-Suef
⁷Departments of Pathology , Faculties of Medicine , King Salman International Universities, Tur Sinai
⁸Departments of Medical Parasitology, Faculties of Medicine , Beni- Suef ,Beni-Suef
Abstract
Background: Possible association between toxoplasmosis, and chronic diseases, e.g., hypertension (HTN) and diabetes mellitus (DM) are not uncommon. Therefore, searching for a new, safe, alternative and efficient natural product to treat toxoplasmosis in patients complaining of hypertension or diabetes is critically needed. Objective: To investigate the potential prophylactic and therapeutic efficacy of berberine on chronic toxoplasmosis in diabetic, and hypertensive mice compared to Spiramycin©. Material and Methods: A total number of 77 mice were divided into normal (n.=7), hypertensive (n.=35) and diabetic (n.=35) mice. Hypertension and type 1 diabetes were induced by 8% NaCl, and 2% Alloxan monohydrate, respectively. Both hypertensive, and diabetic mice were subdivided into five equal subgroups: control, berberine-prophylactic, Spiramycin©-treated, berberine-treated, and combined treatment (berberine and Spiramycin©). Berberine efficacy was assessed using parasitological and histopathological parameters. Results: Parasitological assessment showed that all treated subgroups showed a statistically significant reduction in the median tissue cysts count compared to infected control subgroups. Combined (berberine and Spiramycin©) showed the highest reduction rates of cysts count in both hypertensive and diabetic subgroups. For the prophylactic potential efficacy, berberine showed the least reduction rate in tissue cyst count in both hypertensive and diabetic subgroups. Histopathological assessment demonstrated moderate to marked improvement of brain, spleen and kidney inflammatory changes in all treated subgroups, the highest was recorded in the combined treated subgroups. Conclusion: Berberine is a promising adjuvant in treating toxoplasmosis associated with chronic diseases including diabetes mellitus and hypertension.
Keywords
berberine; diabetes; hypertension; Spiramycin©; toxoplasmosis


Statistics Article View: 127 PDF Download: 261